Supraventricular tachycardia AHA recommendations for Management of AVNRT
|
Supraventricular tachycardia Microchapters |
|
Differentiating Among the Different Types of Supraventricular Tachycardia |
|---|
|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
|
Diagnosis |
|
Treatment |
|
2015 ACC/AHA Guideline Recommendations |
|
Case Studies |
|
Supraventricular tachycardia AHA recommendations for Management of AVNRT On the Web |
|
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of AVNRT |
|
FDA on Supraventricular tachycardia AHA recommendations for Management of AVNRT |
|
CDC on Supraventricular tachycardia AHA recommendations for Management of AVNRT |
|
Supraventricular tachycardia AHA recommendations for Management of AVNRT in the news |
|
Blogs on Supraventricular tachycardia AHA recommendations for Management of AVNRT |
|
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Management of AVNRT
Acute treatment of AVNRT
| Class I |
| "1.Vagal maneuvers are recommended for acute treatment in patients with AVNRT "(Level of Evidence:B-R) " |
| "2.Adenosine is recommended for acute treatment in patients with AVNRT "(Level of Evidence:B-R ) " |
| "3.Synchronized cardioversion should be performed for acute treatment in hemodynamically unstable patients with AVNRT when adenosine and vagal maneuvers do not terminate the tachycardia or are not feasible"(Level of Evidence: B-NR) " |
| "4.Synchronized cardioversion is recommended for acute treatment in hemodynamically stable patients with AVNRT when pharmacological therapy does not terminate the tachycardia or is contraindicated"(Level of Evidence: B-NR) " |
| Class IIa |
| "1.Intravenous beta blockers, diltiazem, or verapamil are reasonable for acute treatment in hemodynamically stable patients with AVNRT"(Level of Evidence: B-R) " |
| Class IIb |
| "1.Oral beta blockers, diltiazem, or verapamil may be reasonable for acute treatment in hemodynamically stable patients with AVNRT "(Level of Evidence:C-LD) " |
Management of ongoing AVNRT
| Class I |
| "1.Oral verapamil or diltiazem is recommended for ongoing management in patients with AVNRT who are not candidates for, or prefer not to undergo, catheter ablation "(Level of Evidence:B-R) " |
| "2.Catheter ablation of the slow pathway is recommended in patients with AVNRT "(Level of Evidence:B-NR ) " |
| "3.Oral beta blockers are recommended for ongoing management in patients with AVNRT who are not candidates for, or prefer not to undergo, catheter ablation"(Level of Evidence: B-R) " |
| Class IIa |
| "1.Flecainide or propafenone is reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have AVNRT and are not candidates for, or prefer not to undergo, catheter ablation and in whom beta blockers, diltiazem, or verapamil are ineffective or contraindicated"(Level of Evidence: B-R) " |
| "2.Clinical follow-up without pharmacological therapy or ablation is reasonable for ongoing management in minimally symptomatic patients with AVNRT"(Level of Evidence: B-NR) " |
| Class IIb |
| "1.Oral sotalol or dofetilide may be reasonable for ongoing management in patients with AVNRT who are not candidates for, or prefer not to undergo, catheter ablation "(Level of Evidence:B-R) " |
| "2.Oral digoxin or amiodarone may be reasonable for ongoing treatment of AVNRT in patients who are not candidates for, or prefer not to undergo, catheter ablation( "(Level of B-R ) " |